Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis

Journal of Alzheimer's Disease

Volumn 51, Issue 1, 2016, Pages 45-55

  Wang, Hua Long ^a   Wang, Yan Yong ^a   Liu, Xin Gang ^b   Kuo, Sheng Han ^c   Liu, Na ^a   Song, Qiao Yun ^d   Wang, Ming Wei ^a,e  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Department of Rehabilitation   (China)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d HEBEI GENERAL HOSPITAL   (China)

^e Brain Aging and Cognitive Neuroscience Laboratory of Hebei Province   (China)

Author keywords

24 hydroxycholesterol; 27 hydroxycholesterol; Alzheimer's disease; cerebrospinal fluid; cholesterol

Indexed keywords

24 HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CHOLESTEROL; CHOLESTEROL DERIVATIVE; TAU PROTEIN; UNCLASSIFIED DRUG; 24-HYDROXYCHOLESTEROL; 27-HYDROXYCHOLESTEROL;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHOLESTEROL METABOLISM; DISEASE MARKER; EFFECT SIZE; GAS CHROMATOGRAPHY; HUMAN; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; BIBLIOGRAPHIC DATABASE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; CHOLESTEROL; COGNITIVE DYSFUNCTION; DATABASES, BIBLIOGRAPHIC; HUMANS; HYDROXYCHOLESTEROLS;

EID: 84960092302     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150734     Document Type: Article

References (44)

1. Blennow K, Zetterberg H (2009) Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 18, 413-417
2. Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, Jessen F, Herukka SK, Soininen H, Maetzler W, Leyhe T, Burger K, Taniguchi M, Urakami K, Lista S, Dubois B, Blennow K, Hampel H (2015) CSF biomarkers for the differential diagnosis of Alzheimer's disease. A large-scale international multicenter study. Alzheimers Dement 11, 1306-1315
3. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, Beel AJ, Sanders CR (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168-1171
4. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer's disease: the cholesterol connection. Nat Neurosci 6, 345-351
5. Mendoza-Oliva A, Ferrera P, Fragoso-Medina J, Arias C (2015) Lovastatin differentially affects neuronal cholesterol and amyloid-beta production in vivo and in vitro. CNS Neurosci Ther 21, 631-641
6. Djelti F, Braudeau J, Hudry E, Dhenain M,Varin J, Bieche I, Marquer C, Chali F, Ayciriex S, Auzeil N, Alves S, Langui D, Potier MC, Laprevote O,Vidaud M, Duyckaerts C, Miles R, Aubourg P, Cartier N (2015) CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain 138, 2383-2398
7. Leoni V, Caccia C (2013) Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid. Biochem Pharmacol 86, 26-36
8. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Bjorkhem I, von Bergmann K, Heun R (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36, 27-32
9. Martinez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM (2014) Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathol 127, 633-643
10. Kolsch H, Lutjohann D, Jessen F, Urbach H, von Bergmann K, MaierW, Heun R (2006) Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease. J Neural Transm 113, 231-238
11. Kolsch H, Lutjohann D, Jessen F, Popp J, Hentschel F, Kelemen P, Schmitz S, MaierW, Heun R (2009) CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism. Eur Psychiatry 24, 183-190
12. Kolsch H, Lutjohann D, Jessen F, Popp J, Hentschel F, Kelemen P, Friedrichs S, Maier TA, Heun R (2009) RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism. J Cell Mol Med 13, 589-598
13. Kolsch H, Heun R, Jessen F, Popp J, Hentschel F, Maier W, Lutjohann D (2010) Alterations of cholesterol precursor levels in Alzheimer's disease. Biochim Biophys Acta 1801, 945-950
14. Qureischie H, Heun R, Lutjohann D, Popp J, Jessen F, Ledschbor-Frahnert C, Thiele H, Maier W, Hentschel F, Kelemen P, Kolsch H (2008) CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk. Brain Res 1232, 1-6
15. Mateos L, Ismail MA, Gil-Bea FJ, Leoni V, Winblad B, Bjorkhem I, Cedazo-Minguez A (2011) Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease. J Alzheimers Dis 24, 669-679
16. Wollmer MA, Streffer JR, Tsolaki M, Grimaldi LM, Lutjohann D, Thal D, von Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A (2003) Genetic association of acyl-coenzyme A: Cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. Mol Psychiatry 8, 635-638
17. Wollmer MA, Streffer JR, Lutjohann D, Tsolaki M, IakovidouV, HegiT, PaschT, Jung HH, Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A (2003) ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24, 421-426
18. Shafaati M, Solomon A, Kivipelto M, Bjorkhem I, Leoni V (2007) Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders. Neurosci Lett 425, 78-82
19. Schonknecht P, Lutjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, Beyreuther K, Schroder J (2002) Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 324, 83-85
20. Popp J, Lewczuk P, Kolsch H, Meichsner S, Maier W, Kornhuber J, Jessen F, Lutjohann D (2012) Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. J Neurochem 123, 310-316
21. Popp J, Meichsner S, Kolsch H, Lewczuk P, Maier W, Kornhuber J, Jessen F, Lutjohann D (2013) Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. Biochem Pharmacol 86, 37-42
22. Vanmierlo T, Popp J, Kolsch H, Friedrichs S, Jessen F, Stoffel-Wagner B, Bertsch T, Hartmann T, Maier W, von Bergmann K, Steinbusch H, Mulder M, Lutjohann D (2011) The plant sterol brassicasterol as additional CSF biomarker in Alzheimer's disease. Acta Psychiatr Scand 124, 184-192
23. Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I (2004) Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 42, 186-191
24. Leoni V, Shafaati M, Salomon A, Kivipelto M, Bjorkhem I, Wahlund LO (2006) Are the CSF levels of 24Shydroxycholesterol a sensitive biomarker for mild cognitive impairment? Neurosci Lett 397, 83-87
25. Leoni V, Solomon A, Lovgren-Sandblom A, Minthon L, Blennow K, Hansson O, Wahlund LO, Kivipelto M, Bjorkhem I (2013) Diagnostic power of 24Shydroxycholesterol in cerebrospinal fluid: Candidate marker of brain health. J Alzheimers Dis 36, 739-747
26. Dietschy JM, Turley SD (2004) Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45, 1375-1397
27. Pfrieger FW (2003) Outsourcing in the brain: Do neurons depend on cholesterol delivery by astrocytes? Bioessays 25, 72-78
28. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331
29. Wang H, Lian K, Han B, Wang Y, Kuo SH, Geng Y, Qiang J, Sun M, Wang M (2014) Age-related alterations in the metabolic profile in the hippocampus of the senescenceaccelerated mouse prone 8: A spontaneous Alzheimer's disease mouse model. J Alzheimers Dis 39, 841-848
30. Wang H, Geng Y, Han B, Qiang J, Li X, Sun M, Wang Q, Wang M (2013) Repetitive transcranial magnetic stimulation applications normalized prefrontal dysfunctions and cognitive-related metabolic profiling in aged mice. PLoS One 8, e81482
31. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57, 1439-1443
32. Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A(2006) Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 185, 63-70
33. Wolozin B (2012) Statins and therapy of Alzheimer's disease: Questions of efficacy versus trial design. Alzheimers Res Ther 4, 3
34. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J (2002) Natural history of mild cognitive impairment in older persons. Neurology 59, 198-205
35. Kivipelto M, Ngandu T, Laatikainen T,Winblad B, Soininen H, Tuomilehto J (2006) Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study. Lancet Neurol 5, 735-741
36. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA (2009) Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 28, 75-80
37. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, Girones X, Henry TL, Matsubara E, Zambon D, Wolozin B, Sano M, Cruz-Sanchez FF, Thal LJ, Petanceska SS, Refolo LM (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199-205
38. Bjorkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U (2006) Oxysterols and Alzheimer's disease. Acta Neurol Scand Suppl 185, 43-49
39. Fonseca AC, Resende R, Oliveira CR, Pereira CM (2010) Cholesterol and statins in Alzheimer's disease: Current controversies. Exp Neurol 223, 282-293
40. Wollmer MA (2010) Cholesterol-related genes in Alzheimer's disease. Biochim Biophys Acta 1801, 762-773
41. Moncaster JA, Pineda R, Moir RD, Lu S, Burton MA, Ghosh JG, Ericsson M, Soscia SJ, Mocofanescu A, Folkerth RD, Robb RM, Kuszak JR, Clark JI, Tanzi RE, Hunter DG, Goldstein LE (2010) Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One 5, e10659
42. Hughes TM, Rosano C, Evans RW, Kuller LH (2013) Brain cholesterol metabolism, oxysterols, and dementia. J Alzheimers Dis 33, 891-911
43. Leoni V (2009) Oxysterols as markers of neurological disease-A review. Scand J Clin Lab Invest 69, 22-25
44. Anstey KJ, Lipnicki DM, Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 16, 343-354.